The Claim
Patients with homozygous familial hypercholesterolemia (HoFH) and LDLR-null/null genotype exhibit minimal response to PCSK9 inhibitors, demonstrated by a mean LDL cholesterol reduction of -4.7% (standard deviation 11.4%), with 77.8% of patients failing to achieve a 15% reduction threshold, indicating limited therapeutic efficacy in this genetic subgroup.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with a rare genetic form of high cholesterol caused by two broken copies of the LDLR gene don’t get much benefit from PCSK9 inhibitor drugs — most see almost no drop in their bad cholesterol.
See the scientific wording
Patients with homozygous familial hypercholesterolemia (HoFH) who have LDLR-null/null genotype show minimal response to PCSK9 inhibitors, with a mean LDL-C reduction of -4.7% (SD 11.4%) and 77.8% failing to achieve the 15% reduction threshold, suggesting these therapies are largely ineffective in this genetic subgroup.
What the research says
1 studyThe study looked at how well PCSK9 inhibitors lower bad cholesterol in people with a rare genetic condition, and found they don’t work well, especially in those with a specific genetic type that the claim talks about.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.